-

03:55:32 PM

GANX Stock News

GANX - Gain Therapeutics Inc

09/26/22 8:00 AM

Nasdaq : GANX

clinical triallow float

Gain Therapeutics Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson's Disease Patient-Derived Dopaminergic Neurons

RHEA-AI

neutral

09/20/22 7:30 AM

Nasdaq : GANX

managementlow float

Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer

Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a biotechnology company transforming drug

RHEA-AI

very positive

09/19/22 8:00 AM

Nasdaq : GANX

clinical triallow float

Gain Therapeutics Presents New Preclinical Data Demonstrating Potential Disease Modifying Benefits of its Novel Brain Penetrant Small Molecule Candidate GT-02287 in Two Preclinical Models of Parkinson's Disease

Treatment with GT-02287 Resulted in a Significant Dose-Dependent Improvement of Cellular Lysosomal Health and Fine Motor Skills Results Presented at the International Congress of Parkinson's Disease and Movement Disorders 2022 Annual Meeting in Madrid, Spain BETHESDA, Md., Sept. 19, 2022 (GLOBE

RHEA-AI

neutral

09/08/22 8:00 AM

Nasdaq : GANX

conferenceslow float

Gain Therapeutics to Present Data at Upcoming Medical Meetings

Gain Therapeutics,

RHEA-AI

neutral

09/06/22 8:00 AM

Nasdaq : GANX

conferenceslow float

Gain Therapeutics To Participate At The H.C. Wainwright 24th Annual Global Investment Conference

Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule

RHEA-AI

neutral

08/04/22 8:00 AM

Nasdaq : GANX

conferenceslow float

Gain Therapeutics to Participate at the 2022 BTIG Biotechnology Conference

Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule

RHEA-AI

neutral

06/02/22 8:00 AM

Nasdaq : GANX

conferenceslow float

Gain Therapeutics to Participate at the Jefferies Healthcare Conference

Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule

RHEA-AI

neutral

05/18/22 8:00 AM

Nasdaq : GANX

conferenceslow float

Gain Therapeutics to Participate at the H.C. Wainwright Global Investment Conference

Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule

RHEA-AI

neutral

05/16/22 4:05 PM

Nasdaq : GANX

earningslow float

Gain Therapeutics, Inc. Reports First Quarter 2022 Financial Results and Business Update

Presented Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Study in Parkinson's Disease and Gaucher's Disease. $34.34 Million in Cash as of March 31, 2022, Provides Runway into Second half of 2023 and a Strong

RHEA-AI

neutral

05/11/22 9:30 AM

Nasdaq : GANX

clinical triallow float

Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium

Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the

RHEA-AI

neutral